North America Pain Relief Devices Market

Overview

The North America pain relief devices market was valued at USD 4.0 billion in 2025 and is projected to reach USD 8.3 billion by 2034, growing at a CAGR of 8.5% during the forecast period (2026-2034). The market is driven by the rising prevalence of chronic pain conditions, increasing preference for non-opioid pain management alternatives, and continuous advancements in neurostimulation and radiofrequency ablation technologies across the United States, Canada, and Mexico. The market is shifting from conventional, open-loop stimulation systems and single-purpose electrotherapy units toward closed-loop, sensor-driven neuromodulation platforms and app-connected wearable devices that personalize therapy to each patient's individual pain profile. Manufacturers are consolidating peripheral nerve stimulation and radiofrequency ablation capabilities through targeted acquisitions, while wearable, prescription-free electrotherapy devices are extending access to pain relief beyond traditional clinical settings and into everyday consumer use. Government initiatives such as the U.S. Department of Veterans Affairs' continued expansion of non-pharmacological pain management coverage for veterans, and the Centers for Medicare and Medicaid Services' ongoing review of reimbursement pathways for neurostimulation and radiofrequency ablation procedures, are supporting broader clinical adoption of device-based pain therapies. Health Canada's regulatory alignment with U.S. Food and Drug Administration clearances for several neurostimulation and electrotherapy devices is similarly reinforcing demand across Canadian provincial healthcare systems. By Country, the United States holds the largest share of the North America pain relief devices market, supported by extensive reimbursement coverage, a dense concentration of pain management specialists, and a strong presence of leading device manufacturers. Canada is projected to be the fastest-growing country market during the forecast period, driven by expanding public healthcare coverage for neuromodulation therapies and rising awareness of non-opioid pain management options.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Consolidation Around Peripheral Nerve Stimulation Technology Emerging as a Transformational Trend

• Peripheral nerve stimulation has moved from a niche therapy to a core growth priority for the largest neuromodulation manufacturers active in North America. Companies that once relied primarily on spinal cord stimulation platforms are now building parallel peripheral nerve stimulation portfolios to reach patients with focal, peripheral pain who are not ideal candidates for more invasive implantable systems.
• Newer peripheral nerve stimulation systems are being engineered around miniaturized, battery-free implantable pulse generators that are powered wirelessly through externally worn transmitters and controlled through smartphone applications. This design approach reduces surgical burden compared with traditional implantable generators and is enabling physicians to offer minimally invasive stimulation therapy earlier in the chronic pain treatment pathway.
• Clinical evidence supporting closed-loop and full-body peripheral nerve stimulation platforms is expanding rapidly, with multi-year randomized controlled trial data now demonstrating durable pain reduction and functional improvement across diverse anatomical locations, including the shoulder, lower back, knee, and craniofacial region. This growing evidence base is strengthening physician confidence and supporting expanded regulatory clearances across therapy areas.
• Boston Scientific announced an agreement to acquire Nalu Medical for approximately USD 600 million in upfront cash, adding Nalu's miniaturized peripheral nerve stimulation system to its existing spinal cord stimulation, basivertebral nerve ablation, and radiofrequency ablation portfolio, with the transaction expected to close in the first half of 2026.

KEY MARKET DRIVER

Rising Preference for Non-Opioid Chronic Pain Management Is Driving Market Growth

• Chronic pain affects a substantial share of the adult population across the United States, Canada, and Mexico, and growing concern over opioid dependence is pushing both physicians and patients toward device-based alternatives. Non-pharmacological pain management devices are increasingly positioned as first-line or early-line therapy options rather than treatments reserved only for patients who have already exhausted medication-based approaches.
• Health systems and payers across North America are placing greater emphasis on reducing long-term opioid prescriptions for conditions such as chronic back pain, diabetic neuropathy, and post-surgical pain. This shift is supporting reimbursement pathways for spinal cord stimulation, peripheral nerve stimulation, and radiofrequency ablation procedures that were previously considered late-stage interventions reserved for the most severe cases.
• Radiofrequency ablation procedures targeting the knee, spine, and sacroiliac joint are being adopted earlier in the treatment continuum for osteoarthritis and facet-related pain, supported by clinical data showing extended pain relief of up to twenty-four months following a single outpatient procedure. This durability is improving the cost-effectiveness case for device-based therapy relative to repeated pharmacological management.
• Enovis Corporation reported full-year 2025 net sales of USD 2.2 billion, with its Prevention and Recovery segment, which includes electrical stimulation-based pain management products, contributing meaningfully to overall company growth and reflecting sustained clinical and consumer demand for non-invasive pain therapy across North America.

Key Market Opportunity

Expansion of Wearable, Prescription-Free Electrotherapy Devices Creates New Growth Opportunity

• Rising consumer interest in self-managed pain relief is creating demand for compact, wearable electrotherapy and vagus nerve stimulation devices that can be used without an implant procedure. These products are expanding the addressable market beyond traditional hospital and clinic-based patients to include consumers seeking convenient, drug-free relief for conditions such as fibromyalgia and migraine.
• Direct-to-consumer distribution channels, including e-commerce platforms and pharmacy partnerships, are lowering the barrier to access for non-invasive pain relief wearables. This is allowing device manufacturers to reach patients earlier in their pain management journey, well before they would otherwise be referred to an interventional pain specialist or neurosurgeon.
• Manufacturers are pairing wearable electrotherapy devices with companion mobile applications that track usage patterns, pain scores, and therapy outcomes over time. This data-driven approach is creating opportunities for manufacturers to demonstrate long-term value to payers and to support future reimbursement expansion for currently self-pay wearable device categories.
• electroCore reported that cumulative sales of its Quell Fibromyalgia wearable transcutaneous nerve stimulation device reached approximately USD 4.0 million since its May 2025 launch, with second-quarter 2026 Quell sales growing nearly 700% year-over-year, reflecting rapid early consumer adoption of prescription-free electrotherapy wearables 

North America Pain Relief Devices Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Product Type

Neurostimulation devices held the largest share of the market in 2025, supported by their proven clinical efficacy in managing chronic neuropathic and intractable pain that has not responded to conservative therapy. Spinal cord stimulation and peripheral nerve stimulation systems from established manufacturers are backed by multi-year randomized controlled trial data demonstrating sustained pain reduction, improved functionality, and meaningful reductions in opioid consumption among treated patients. Favorable reimbursement coverage from the Centers for Medicare and Medicaid Services and major private payers has further accelerated adoption across pain management centers, neurosurgery practices, and ambulatory surgical centers. Continued platform innovation, including closed-loop sensing, artificial intelligence-driven programming, and expanded MRI compatibility, is reinforcing physician preference for neurostimulation over less durable pain management alternatives, sustaining its leadership position through the forecast period.

Radiofrequency ablation devices are projected to register the fastest CAGR among product types during the forecast period, driven by growing physician and patient preference for minimally invasive, outpatient procedures that avoid general anesthesia and extended recovery times. Cooled and conventional radiofrequency ablation systems targeting the knee, spine, and sacroiliac joint are increasingly used earlier in the chronic pain treatment continuum for osteoarthritis and facet-related conditions, supported by clinical evidence showing pain relief lasting up to twenty-four months following a single treatment. Manufacturers are expanding their radiofrequency ablation portfolios through targeted acquisitions of specialized probe and generator technology providers, strengthening product breadth and geographic reach across the United States and Canada. Rising outpatient procedure volumes at ambulatory surgical centers are expected to continue supporting above-average growth for this segment.

Product Type categories include

• Neurostimulation Devices (Dominating Segment)
• Radiofrequency Ablation Devices (Highest CAGR Segment)
• Electrotherapy Devices
• Analgesic Infusion Pumps
• Others (Cryotherapy Devices, Interferential Current Devices)

Analysis by Application

Neuropathic pain held the largest share of the market in 2025, reflecting the high prevalence of conditions such as diabetic peripheral neuropathy, failed back surgery syndrome, and complex regional pain syndrome across the region's aging population. Spinal cord stimulation and peripheral nerve stimulation systems have accumulated substantial clinical evidence specifically validating their effectiveness for neuropathic pain indications, resulting in well-established reimbursement pathways and strong specialist referral networks. Leading device manufacturers continue to pursue expanded regulatory indications specifically covering neuropathic pain sub-types, further reinforcing this segment's clinical credibility. The combination of an aging population, rising diabetes prevalence, and growing recognition of neuropathic pain as a distinct, device-treatable condition is expected to sustain its market-leading position through 2034.

Cancer pain is projected to grow at the fastest CAGR among the application segment during the forecast period, supported by improving long-term survival rates among cancer patients that have increased clinical focus on sustained quality-of-life and pain management throughout extended treatment and survivorship periods. Analgesic infusion pumps and targeted neurostimulation therapies are increasingly integrated into multidisciplinary oncology pain management protocols, particularly for patients whose pain is poorly controlled by systemic opioid therapy alone. Growing awareness among oncologists and palliative care specialists regarding device-based options for refractory cancer pain is expanding referral pathways into interventional pain management. As cancer survivorship continues to rise across the United States, Canada, and Mexico, demand for device-based cancer pain management is projected to grow at an above-average pace.

Application categories include

• Neuropathic Pain (Dominating Segment)
• Cancer Pain (Highest CAGR Segment)
• Musculoskeletal Pain
• Post-Surgical Pain
• Migraine and Headache Disorders

Analysis by End User

Hospitals and clinics held for the largest share of the market in 2025, reflecting the concentration of implantable device procedures, including spinal cord stimulation and peripheral nerve stimulation trials and implants, within hospital-based and specialized pain clinic settings. These facilities offer the surgical infrastructure, imaging capability, and post-procedure monitoring required for implantable neurostimulation and radiofrequency ablation therapies, making them the primary site of care for higher-acuity chronic pain patients. Multidisciplinary pain management programs within hospital systems also support comprehensive patient evaluation prior to device selection, reinforcing referral volumes into this end-user category. Continued investment in dedicated interventional pain suites within hospital networks across the United States is expected to sustain this segment's leading position.

Home care settings are projected to grow at the fastest rate among end-user categories through the forecast period, driven by rising adoption of portable, prescription-based and over-the-counter electrotherapy devices that allow patients to self-administer pain relief therapy outside clinical facilities. Shorter hospital stays, cost containment pressures within North American healthcare systems, and strong patient preference for convenient, at-home pain management are accelerating this shift. Wearable transcutaneous electrical nerve stimulation and vagus nerve stimulation devices, supported by companion mobile applications, are enabling remote therapy tracking and reducing the need for frequent in-person follow-up visits. As device manufacturers continue to expand direct-to-consumer distribution channels, home care settings are expected to capture a growing share of overall device utilization.

End User categories include

• Hospitals and Clinics (Dominating Segment)
• Home Care Settings (Highest CAGR Segment)
• Physiotherapy Centers
• Rehabilitation Centers
• Ambulatory Surgical Centers

Analysis by Mode of Purchase

Prescription-based devices held the largest share of the market in 2025, reflecting the continued dominance of implantable neurostimulation systems, radiofrequency ablation equipment, and clinically supervised electrotherapy devices that require physician evaluation, fitting, and ongoing management. Insurance reimbursement structures across the United States and Canada are generally aligned with prescription-based device categories, providing manufacturers with established billing codes and payer relationships that support continued clinical adoption. Physician oversight also allows for more precise patient selection and therapy customization, which has historically translated into stronger clinical outcomes and payer confidence in device-based pain management. This established reimbursement and clinical infrastructure is expected to keep prescription-based devices as the leading purchase category through the forecast period.

Over-the-counter devices are projected to be the fastest-growing purchase category during the forecast period, driven by rising consumer interest in self-managed, drug-free pain relief for common conditions such as muscle soreness, minor joint pain, and tension headaches. Expanding retail and e-commerce availability of compact transcutaneous electrical nerve stimulation and neuromuscular electrical stimulation units is lowering the cost and convenience barriers that previously limited consumer adoption. Growing consumer wellness trends and increased comfort with wearable health technology are further supporting demand for over-the-counter pain relief devices among younger and more health-conscious demographics. As manufacturers continue to introduce app-connected, consumer-friendly designs, this category is expected to expand at an above-average pace across the United States, Canada, and Mexico.

Mode of Purchase categories include

• Prescription-Based Devices (Dominating Segment)
• Over-the-Counter Devices (Highest CAGR Segment)

By Region

The United States accounted for the largest share of the North America pain relief devices market in 2025, supported by its dense concentration of pain management specialists, extensive network of ambulatory surgical centers, and the presence of leading global device manufacturers, including Medtronic, Boston Scientific, Abbott, and Globus Medical. Favorable reimbursement pathways through the Centers for Medicare and Medicaid Services and major private insurers have supported broad clinical adoption of spinal cord stimulation, peripheral nerve stimulation, and radiofrequency ablation therapies. The U.S. Department of Veterans Affairs' continued expansion of non-pharmacological pain management programs is further reinforcing device adoption among the veteran population. Ongoing FDA approvals for expanded indications, including prone MRI compatibility and multi-site pain coverage, continue to strengthen the competitive positioning of the U.S. market within the broader North American region.

Canada is projected to register the fastest CAGR within the North America pain relief devices market during the forecast period, supported by expanding provincial healthcare coverage for neuromodulation therapies and rising public awareness of non-opioid pain management alternatives amid ongoing efforts to curb opioid-related harm. Growing investment in interventional pain management infrastructure across major Canadian metropolitan hospitals is improving patient access to spinal cord stimulation and radiofrequency ablation procedures. Health Canada's regulatory alignment with U.S. Food and Drug Administration clearances for several neurostimulation and electrotherapy devices is also facilitating faster market entry for leading manufacturers. Rising adoption of home-based electrotherapy devices among Canada's aging population is expected to further support above-average growth across the country through 2034.

Countries and Regions Covered

• United States (Largest Country Market)
• Canada (Fastest-Growing Country Market)
• Mexico

Market Share

The North America pain relief devices market is consolidated, with a small group of large, diversified medical device companies, including Medtronic, Boston Scientific, Abbott, and Globus Medical, holding leading positions through broad neuromodulation portfolios, extensive clinical evidence, and established payer relationships. Alongside these leaders, a growing number of focused peripheral nerve stimulation and radiofrequency ablation specialists, such as Curonix, Neuros Medical, and Avanos Medical, are strengthening competition in specific therapy niches. Key success factors include depth of clinical evidence, breadth of regulatory indications, and strength of physician training networks. Leading companies are prioritizing acquisitions of complementary peripheral nerve stimulation technology, expansion of wearable and home-use device portfolios, and continued investment in closed-loop and artificial intelligence-enabled neurostimulation platforms to sustain competitive differentiation through the forecast period.

Key Players

• Medtronic plc (Ireland)
• Boston Scientific Corporation (United States)
• Abbott Laboratories (United States)
• Globus Medical, Inc. (United States)
• Enovis Corporation (United States)
• Zynex, Inc. (United States)
• Avanos Medical, Inc. (United States)
• OMRON Healthcare, Inc. (Japan)
• electroCore, Inc. (United States)
• BioElectronics Corporation (United States)
• Neuros Medical, Inc. (United States)
• Saluda Medical Pty Ltd (Australia)
• Cefaly Technology (Belgium)
• Theranica Bio-Electronics Ltd. (Israel)
• Curonix LLC (United States)
• Bioventus Inc. (United States)

Recent Market Developments

• In January 2025, Curonix LLC announced expanded MR labeling for its Freedom Peripheral Nerve Stimulator System to include full-body 3T MRI scans, making it the first permanent peripheral nerve stimulation system in the United States that is MR conditional across the entire body at both 1.5T and 3T field strengths.
• In February 2025, Globus Medical, Inc. completed its acquisition of Nevro Corp., adding Nevro's HFX spinal cord stimulation platform to its musculoskeletal technology portfolio and unlocking what the company described as a USD 2 billion neuromodulation market opportunity for chronic pain treatment.
• In October 2025, Boston Scientific announced an agreement to acquire Nalu Medical for approximately USD 600 million in upfront cash, adding a miniaturized, battery-free peripheral nerve stimulation system to its existing spinal cord stimulation and radiofrequency ablation portfolio.
• In January 2026, Curonix LLC announced commercial availability of its Freedom Peripheral Nerve Stimulator System for chronic craniofacial pain, becoming the first and only full-body peripheral nerve stimulation therapy available in the United States for this indication, supported by data from an FDA-approved investigational device exemption study.

Frequently Asked Questions